The gut microbe Bacteroides acidifaciens ameliorates CCl4-induced liver fibrosis
European Journal of Pharmacology · 2025
DOI: 10.1016/j.ejphar.2025.178265 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Fangyu Ye und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 211198, Nanjing, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Liver Cirrhosis, Bacteroides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND & AIMS: Liver fibrosis is an inevitable outcome of various manifestations of progressive chronic liver disease. Clinical evidence suggests that gut microbiota contributes to the progression of liver fibrosis via gut-liver axis. Our previous research demonstrated that GL-V9, one of flavonoids compounds, is effective in alleviating liver fibrosis in mice. Based on that, we decided to delve into the alterations in gut microbiota profiling of GL-V9-treated mice with liver fibrosis and identify the bacterial species exhibiting anti-fibrotic potential. METHODS: We explored gut microbial profile of GL-V9-treated mice with liver fibrosis via 16S rRNA gene sequencing. Mouse models of liver fibrosis were established and treated accordingly. Then, indexes of liver fibrosis and inflammation were measured by sections staining, biochemical detection and RT-qPCR. Regulatory T (Treg) cells infiltration was detected by flow cytometry. Furthermore, we detected short-chain fatty acids (SCFAs) content by GC-MS and explored the role of SCFAs in liver fibrosis. RESULTS: Firstly, Bacteroides acidifaciens were screened out by 16S rRNA gene sequencing based on GL-V9 treatment. Oral administration of Bacteroides acidifaciens attenuated CCl4-induced liver fibrosis effectively, reduced the expressions of pro-inflammatory factor and suppressed the infiltration of Treg cells. Additionally, SCFAs, the main metabolites of Bacteroides acidifaciens, were further demonstrated the suppression of fibrosis and inflammation. Mechanistically, Bacteroides acidifaciens regulated SCFAs metabolic homeostasis and subsequently inhibited Treg cells infiltration via regulating PI3K/AKT/mTOR pathway. CONCLUSIONS: In CCl4-induced liver fibrosis mice, Bacteroides acidifaciens and its derived SCFAs exhibit excellent anti-fibrosis effects, which provides a new strategy for liver fibrosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 211198, Nanjing, China.
- Target Discovery Center, China Pharmaceutical University, 211198, Nanjing, China.
- The Animal Experimental Center of China Pharmaceutical University, 211198, Nanjing, China.
- School of Medicine, Tibet University, 850000, Lhasa, China.
- The First Clinical Medical College, Nanjing University of Chinese Medicine, 210023, Nanjing, China.
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China. Electronic address: jp.yu@cpu.edu.cn.
Zitieren
APA
Ye, F., Hou, Y., Huang, M., Guo, Y., Ye, Y., Liu, Y., Zou, L., Bao, Y., Yuan, R., Zhu, F., Yu, J., & Zhao, L. (2025). The gut microbe Bacteroides acidifaciens ameliorates CCl4-induced liver fibrosis. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178265
Vancouver
Ye F, Hou Y, Huang M, Guo Y, Ye Y, Liu Y, et al. The gut microbe Bacteroides acidifaciens ameliorates CCl4-induced liver fibrosis. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.178265
BibTeX
@article{Ye2025,
author = {Ye, Fangyu and Hou, Yingjian and Huang, Min and Guo, Yabing and Ye, Yuting and Liu, Yuehua and Zou, Lin and Bao, Yufan and Yuan, Ruiying and Zhu, Fangke and Yu, Juping and Zhao, Li},
title = {The gut microbe Bacteroides acidifaciens ameliorates CCl4-induced liver fibrosis},
journal = {European Journal of Pharmacology},
year = {2025},
doi = {10.1016/j.ejphar.2025.178265}
}
EUVIMED